Evidence map›Paper›PMID 41184144›Full record

ArticleInvestigative and clinical urology2025

The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer.

Hyomyoung Lee, Sang Won So, Jang Hee Han, Hyeong Dong Yuk, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Seung-Hwan Jeong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative and clinical urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyomyoung LeeDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0009-0002-0715-6609
Sang Won SoDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-9428-4272
Jang Hee HanDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0003-4942-4632
Hyeong Dong YukDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-5874-9167
Chang Wook JeongDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-2200-5019
Ja Hyeon KuDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-0391-2342
Cheol KwakDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-1987-2111
Seung-Hwan JeongDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-8076-3643

Funding

Korea Health Industry Development Institute HI23C1575SNU
6 · The paper itself

Abstract

purposeThis study aimed to evaluate whether the pathological findings from repeat transurethral resection of bladder (re-TURB) predict Bacillus Calmette-Guérin (BCG) response in patients with T1 high-grade bladder cancer. MATERIALS AND

methodsWe analyzed patients with bladder cancer enrolled in the prospective patient registry system of Seoul National University, SUPER-UC, from March 2016 to May 2022. Patients with T1 high-grade cancer who underwent re-TURB and BCG instillation were identified. Re-TURB pathology and its relationship with BCG response were analyzed.

resultsOut of a total of 2,673 patients with bladder cancer, 539 had T1 high-grade bladder cancer. Among these, 251 patients underwent subsequent re-TURB and BCG instillation. Of the 251 patients, 210 (83.7%) were male, and TURB was performed as the initial procedure in 232 cases (92.4%). In the TURB specimens of T1 high-grade cancer, concomitant carcinoma

conclusionsThe pathological results of re-TURB play a critical role in determining the BCG response in patients with T1 high-grade bladder cancer.

Indexed as

Adjuvants, ImmunologicBCG VaccineCystectomyUrinary Bladder NeoplasmsAdministration, IntravesicalAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProspective StudiesReoperationTreatment OutcomeAdjuvants, ImmunologicBCG VaccineBCGBladder cancerNMIBCPathologyTransurethral resection of bladder

Identifiers

PMID41184144
PMCPMC12599427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.